Immuron Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMRN research report →
Price Chart
About the company
Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Research and Development, and Hyperimmune Products—the company serves markets in Australia, Israel, Canada, the United States, and other international regions. Its current product portfolio includes Travelan, an over-the-counter remedy aimed at reducing the likelihood of travelers' diarrhea and minor gastrointestinal complaints, which also functions as a dietary supplement for digestive well-being and gut protection.
- CEO
- Steven George Lydeamore
- IPO
- 2017
- Employees
- 7
- HQ
- Carlton, VIC, AU
Get TickerSpark's AI analysis on IMRN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.26M
- P/E
- -2.87
- PEG
- -0.05
- P/S
- 1.55
- P/B
- 1.09
- EV/EBITDA
- -0.62
- Div Yield
- 0.00%
- Gross Margin
- 64.50%
- Op Margin
- -61.39%
- Net Margin
- -49.77%
- ROE
- -31.88%
- ROIC
- -36.35%
Latest fiscal year · YoY change
- Revenue
- $7.55M+3.5%
- Gross Profit
- $4.87M+2.1%
- Op Income
- $-4,632,000
- Net Income
- $-3,754,817+28.0%
- EPS
- $-0.50+44.2%
- OCF Growth
- +51.1%
- FCF Growth
- +51.1%
- 52W High
- $1.99
- 52W Low
- $0.68
- 50D MA
- $1.03
- 200D MA
- $1.01
- Beta
- 0.51
- RSI (14)
- 35
- Avg Volume
- 2.06M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Immuron said FY2023 revenue was already running well ahead of plan, supported by a rebound in travel and stronger Travelan sales, while it ended the period with a cash position above its market value and outlined an aggressive push on marketing, FDA filings, and possible M&A.· September 6, 2022
- Cash and equivalents were A$22.1 million as of 30 July 2022, versus a market cap of about A$20 million, and management emphasized an “extremely strong balance sheet.”
- FY2023 revenue was said to have exceeded budget by 92%, driven largely by the resurgence in global travel.
- Commercial revenue grew 425% year over year, with growth in both Australia and the rest of world (including the U.S. and Canada).
- Management said the commercial business is “almost breakeven” and aims to get back to a prior run-rate of around $3 million and then grow beyond it.
- Near-term priorities include filing an FDA IND for Travelan, resolving the CampETEC clinical hold, advancing IMM-529 after market review, and expanding distribution/marketing in the U.S., Canada, and Australia.
Immuron reported cash and cash equivalents of A$22.1 million as of 30 July 2022 and said it had essentially no debt aside from a lease commitment. Management also said the company’s market capitalization was about A$20.5 million (23 August 2022). On the operating side, it said FY2023 revenue exceeded budget by 92%, commercial revenue grew 425% year over year, and the commercial side of the business was “almost breakeven.” The company did not provide a detailed income statement in the transcript, but said Travelan and Protectyn had brought the business back toward a pre-pandemic run rate of around $3 million. Forward-looking items included filing an IND for Travelan soon, starting the first clinical trial in the first half of next year upon IND approval, and aiming for topline results before year-end; management also discussed a U.S. Travelan trial, CampETEC resolution, and IMM-529 planning into 2024.
Steven Lydeamore struck an upbeat, turnaround-oriented tone and repeatedly framed the company as undervalued relative to its cash and pipeline. He said he is reviewing the portfolio, commercial channels, and growth drivers, with a strategy built around organic growth plus M&A. His message was that Immuron should communicate more, execute on planned milestones, and use its cash to grow shareholder value rather than simply sit on the balance sheet.
No separate CFO spoke on the call, but management provided several finance-related comments. Lydeamore said cash and equivalents were A$22.1 million, there was essentially no debt, and the business had a lease commitment as the only other non-current liability. He highlighted that commercial revenue was up 425% year over year and that the commercial business was almost breakeven, with a prior run-rate around $3 million before the pandemic. He also said management intends to deploy capital into marketing, distribution expansion, and selective M&A, while preserving a strong balance sheet.
Analysts and shareholders focused heavily on the disconnect between Immuron’s market cap and its cash balance, and management was asked how it would lift the share price above cash backing. Lydeamore said the answer is execution: improved marketing for Travelan, broader U.S. and Canada distribution, more communication with investors, and possible M&A. Questions also covered market awareness, Amazon out-of-stock issues, and the Travelan FDA path; management said the Amazon issue is transitional as it moves from a third-party seller to a direct Immuron store, and that the company is close to filing the IND. On Europe, management said one patent was approved and another is expected soon; on a prior acquisition failure and SARS-CoV-2 work, he said the opportunity had passed and Immuron is not pursuing a JV or legal action.
The bull case from this call is that Immuron has real cash, real commercial products, and a pipeline that management says is advancing toward key regulatory milestones. Travelan appears to be benefiting from travel normalization, and management sees meaningful upside from better U.S./Canada distribution, stronger marketing, and direct online selling. The company also has multiple shots on goal through clinical programs and could add value through M&A or partnerships.
The main risk highlighted was execution: management acknowledged weak market awareness, poor historical communication, and the need to spend marketing dollars more effectively. Some programs are delayed or uncertain, including CampETEC being on clinical hold, IMM-529 still under market review, and a prior SARS-CoV-2 opportunity being abandoned because a mechanism of action was not established. Management also conceded that Canada is not performing well and that the Amazon channel is temporarily out of stock during a transition.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.2%
- Shares Outstanding
- 8.07M
- Float Shares
- 6.87M
of shares held by institutions
6 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bnp Paribas Financial Markets | 49.55K | ▲ 44.35K |
| Hrt Financial LP | 33.40K | ▲ 12.81K |
| Jane Street Group, LLC | 33.26K | ▲ 33.26K |
| Ubs Group AG | 22.51K | ▲ 22.15K |
| Citadel Advisors LLC | 14.69K | ▼ 28.43K |
| Rhumbline Advisers | 3.83K | ▼ 3.53K |
| Caitong International Asset Management Co., Ltd | 28 | ▲ 28 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Palumbo Flavio | other | 0 |
| Oct 24, 24 | Palumbo Flavio | other | 0 |
| Nov 24, 25 | Pollock Daniel Jude | other | 0 |
| Mar 18, 26 | Pollock Daniel Jude | other | 0 |
| Dec 8, 25 | Pollock Daniel Jude | other | 0 |
| Mar 18, 26 | Pollock Daniel Jude | other | 0 |
| Nov 24, 25 | Brennan Paul Gerard | other | 0 |
| Nov 24, 24 | Brennan Paul Gerard | other | 0 |
| Mar 18, 26 | Kanellos Jerry | other | 0 |
| Oct 24, 24 | Kanellos Jerry | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMRN coverage
Recent articles, reports, and earnings notes.
No research on IMRN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMRN report →Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
globenewswire.com · Nov 10
Immuron continued quarterly sales growth
globenewswire.com · Oct 27
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference
globenewswire.com · Oct 22
Travelan® Phase 2 Study Results Published
globenewswire.com · Oct 13
Immuron (NASDAQ:IMRN) Sees Significant Increase in Short Interest
defenseworld.net · Sep 28
Immuron (NASDAQ:IMRN) Shares Down 2.5% – What’s Next?
defenseworld.net · Sep 27
Immuron Stock Surges Friday: What's Driving the Action?
benzinga.com · Sep 4
Immuron to launch PROIBS® in the United States
globenewswire.com · Sep 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.